Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
KPTI's Cash to Debt is ranked higher than
86% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.33 vs. KPTI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
KPTI' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: 10000.00 Max: No Debt
Current: No Debt

Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6679
N/A
No Debt
Equity to Asset 0.92
KPTI's Equity to Asset is ranked higher than
95% of the 704 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. KPTI: 0.92 )
Ranked among companies with meaningful Equity to Asset only.
KPTI' s Equity to Asset Range Over the Past 10 Years
Min: -21.26  Med: 0.95 Max: 0.98
Current: 0.92
-21.26
0.98
F-Score: 4
Z-Score: 6.71
M-Score: 0.35
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -48110.00
KPTI's Operating margin (%) is ranked lower than
100% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.73 vs. KPTI: -48110.00 )
Ranked among companies with meaningful Operating margin (%) only.
KPTI' s Operating margin (%) Range Over the Past 10 Years
Min: -47630.4  Med: -8772.61 Max: -2506.31
Current: -48110
-47630.4
-2506.31
Net-margin (%) -47669.20
KPTI's Net-margin (%) is ranked lower than
100% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.01 vs. KPTI: -47669.20 )
Ranked among companies with meaningful Net-margin (%) only.
KPTI' s Net-margin (%) Range Over the Past 10 Years
Min: -47272.4  Med: -8771.83 Max: -2505.99
Current: -47669.2
-47272.4
-2505.99
ROE (%) -53.26
KPTI's ROE (%) is ranked lower than
89% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.15 vs. KPTI: -53.26 )
Ranked among companies with meaningful ROE (%) only.
KPTI' s ROE (%) Range Over the Past 10 Years
Min: -58.34  Med: -53.44 Max: -41.9
Current: -53.26
-58.34
-41.9
ROA (%) -49.66
KPTI's ROA (%) is ranked lower than
91% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.68 vs. KPTI: -49.66 )
Ranked among companies with meaningful ROA (%) only.
KPTI' s ROA (%) Range Over the Past 10 Years
Min: -372.3  Med: -54.24 Max: -40.03
Current: -49.66
-372.3
-40.03
ROC (Joel Greenblatt) (%) -3537.08
KPTI's ROC (Joel Greenblatt) (%) is ranked lower than
94% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.13 vs. KPTI: -3537.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
KPTI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -11974.25  Med: -4851.30 Max: -3143.6
Current: -3537.08
-11974.25
-3143.6
» KPTI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

KPTI Guru Trades in

Q2 2014

KPTI Guru Trades in Q2 2014

Paul Tudor Jones 15,000 sh (New)
Steven Cohen 8,000 sh (unchged)
» More
Q3 2014

KPTI Guru Trades in Q3 2014

Steven Cohen 39,400 sh (+392.50%)
Paul Tudor Jones Sold Out
» More
Q4 2014

KPTI Guru Trades in Q4 2014

Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with KPTI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NAS:DRRX, NAS:ARLZ, NAS:SNDX, NAS:COLL, OTCPK:TWMJF, NAS:RIGL, NAS:AGRX, OTCPK:SCLRF, OTCPK:ORXOY, OTCPK:CVNZF, NAS:ADMS, NAS:TTPH, OTCPK:SENZ, NAS:BPTH, NAS:FLXN, NAS:NEOS, OTCPK:ELTP, NAS:CPHR, NAS:MSLI, NAS:AQXP » details
Traded in other countries:25K.Germany,
Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and subsequent commercialization of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.

Ratios

vs
industry
vs
history
P/B 1.44
KPTI's P/B is ranked higher than
76% of the 823 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. KPTI: 1.44 )
Ranked among companies with meaningful P/B only.
KPTI' s P/B Range Over the Past 10 Years
Min: 1  Med: 3.93 Max: 10.63
Current: 1.44
1
10.63
P/S 1018.57
KPTI's P/S is ranked lower than
99% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.74 vs. KPTI: 1018.57 )
Ranked among companies with meaningful P/S only.
KPTI' s P/S Range Over the Past 10 Years
Min: 103.74  Med: 2490.84 Max: 16895
Current: 1018.57
103.74
16895
EV-to-EBIT -0.99
KPTI's EV-to-EBIT is ranked lower than
99.99% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.71 vs. KPTI: -0.99 )
Ranked among companies with meaningful EV-to-EBIT only.
KPTI' s EV-to-EBIT Range Over the Past 10 Years
Min: -26.3  Med: -6.75 Max: 1.6
Current: -0.99
-26.3
1.6
EV-to-EBITDA -0.99
KPTI's EV-to-EBITDA is ranked lower than
99.99% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.97 vs. KPTI: -0.99 )
Ranked among companies with meaningful EV-to-EBITDA only.
KPTI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -26.4  Med: -6.80 Max: 1.6
Current: -0.99
-26.4
1.6
Current Ratio 10.45
KPTI's Current Ratio is ranked higher than
91% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. KPTI: 10.45 )
Ranked among companies with meaningful Current Ratio only.
KPTI' s Current Ratio Range Over the Past 10 Years
Min: 0.49  Med: 16.89 Max: 47.98
Current: 10.45
0.49
47.98
Quick Ratio 10.45
KPTI's Quick Ratio is ranked higher than
93% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.78 vs. KPTI: 10.45 )
Ranked among companies with meaningful Quick Ratio only.
KPTI' s Quick Ratio Range Over the Past 10 Years
Min: 0.49  Med: 16.89 Max: 47.98
Current: 10.45
0.49
47.98

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.11
KPTI's Price/Net Cash is ranked higher than
88% of the 253 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.32 vs. KPTI: 2.11 )
Ranked among companies with meaningful Price/Net Cash only.
KPTI' s Price/Net Cash Range Over the Past 10 Years
Min: 2.1  Med: 4.74 Max: 10.95
Current: 2.11
2.1
10.95
Price/Net Current Asset Value 2.08
KPTI's Price/Net Current Asset Value is ranked higher than
88% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.25 vs. KPTI: 2.08 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
KPTI' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.06  Med: 4.67 Max: 10.7
Current: 2.08
2.06
10.7
Price/Tangible Book 1.45
KPTI's Price/Tangible Book is ranked higher than
80% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.59 vs. KPTI: 1.45 )
Ranked among companies with meaningful Price/Tangible Book only.
KPTI' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.7  Med: 4.18 Max: 10.51
Current: 1.45
1.7
10.51
Price/Median PS Value 0.41
KPTI's Price/Median PS Value is ranked higher than
94% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.14 vs. KPTI: 0.41 )
Ranked among companies with meaningful Price/Median PS Value only.
KPTI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.06  Med: 1.02 Max: 6.15
Current: 0.41
0.06
6.15
Earnings Yield (Greenblatt) (%) -99.99
KPTI's Earnings Yield (Greenblatt) (%) is ranked lower than
98% of the 844 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. KPTI: -99.99 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
KPTI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -99.99  Med: 145.45 Max: 344.4
Current: -99.99
-99.99
344.4

More Statistics

Revenue (TTM) (Mil) $0.25
EPS (TTM) $ -3.33
Short Percentage of Float15.67%
52-Week Range $4.83 - 22.61
Shares Outstanding (Mil)35.96

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $)
EPS ($) -2.87 -2.51 -2.46
EPS w/o NRI ($) -2.87 -2.51 -2.46
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for KPTI

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Karopharm Therapeuticcs Inc., Methode Electronics Inc., Gilead Sciences Jul 06 2014 

More From Other Websites
Karyopharm to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference Jul 06 2016
Karyopharm to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference Jul 06 2016
Coverage initiated on Karyopharm Therapeutics by Robert W. Baird Jun 28 2016
Karyopharm Commences First Stage Clinical Study With KPT-9274 Jun 22 2016
Karyopharm Initiates Phase 1 Clinical Trial with KPT-9274 Jun 22 2016
Karyopharm Initiates Phase 1 Clinical Trial with KPT-9274 Jun 22 2016
KARYOPHARM THERAPEUTICS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 17 2016
Karyopharm Outlines Key Selinexor Clinical Development Achievements Jun 16 2016
Karyopharm Outlines Key Selinexor Clinical Development Achievements Jun 16 2016
Karyopharm to Present at the 2016 JMP Securities Life Science Conference Jun 15 2016
Karyopharm to Present at the 2016 JMP Securities Life Science Conference Jun 15 2016
Karyopharm Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : KPTI-US :... Jun 13 2016
Karyopharm Presents Preliminary STOMP Phase 1b Clinical Data at 2016 European Hematology Association... Jun 10 2016
Karyopharm Presents Preliminary STOMP Phase 1b Clinical Data at 2016 European Hematology Association... Jun 10 2016
Karyopharm to Present at the Jefferies 2016 Healthcare Conference Jun 01 2016
Karyopharm to Present at the Jefferies 2016 Healthcare Conference Jun 01 2016
Karyopharm Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : KPTI-US : May... May 25 2016
Karyopharm to Present Preliminary STOMP Phase 1B Clinical Data at 2016 European Hematology... May 19 2016
Karyopharm to Present Preliminary STOMP Phase 1B Clinical Data at 2016 European Hematology... May 19 2016
Karyopharm to Present Selinexor Clinical Data at the American Society of Clinical Oncology Annual... May 18 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)